Abstract:Background Cell death during tissue injury leads to release of chromosomal DNA which is promptly degraded. However, short DNA fragments wrapped around nucleosomes survive longer in the bloodstream and can be isolated as circulating cell-free DNA (ccfDNA). Oncology field pioneered the use of cfDNA as clinical biomarker by identifying sequence modifications induced in cancer cells. Importantly, ccfDNA also retains the same epigenetic information as the tissue of origin. Despite major advances for disease diagnosis and therapy, coronary artery diseases (CAD) and associated conditions such acute myocardial infarction (AMI) or heart failure (HF) are responsible for leading number of deaths worldwide. Preventive and surveillance strategies with non-invasive testing are needed. Purpose Evaluation of ccfDNA methylation profiles as prognostic non-invasive biomarker for risk stratification of acute coronary syndromes and their potential application in preventive and surveillance strategies in other cardiovascular disorders. Methods CcfDNA isolated from citrate-plasma collected from our discovery cohort, comprising healthy controls, STEMI, NSTEMI and unstable angina (UA) patients, was analyzed applying Whole Genome Bisulfite Sequencing (WGBS) using a low-input BS-seq (PBAT) protocol. Computational analysis generated differentially methylated regions (DMRs) by tiling CpG areas and setting a threshold of minimal 25% methylation difference compared to the healthy group. To assess the validity of our findings, a selection of disease-specific DMRs were tested using targeted methylation sequencing protocol in a new set of patients. This procedure consisted in enzymatic conversion of ccfDNA methylated sites followed by probe-specific enrichment libraries and sequencing at a Novaseq 6000 platform. Results The study identified a total of 1941 DMRs and from those 486 were STEMI, 223 NSTEMI and 684 UA specific. From the identified DMRs, 74.13% from STEMI, 72.68% from NSTEMI and 61.62% from UA annotated with heart-related diseases using DisGeNET gene-disease associations. Interestingly, most of identified DMRs located within intronic regions (~60%) and also annotated as enhancers and lncRNAs. The independent validation with targeted methylation sequencing identified 566, 306 and 248 DMRs, respectively, and reduced the number of disease-specific DMRs to 171 in STEMI, 115 in NSTEMI and 82 in UA. Conclusion and Future Approaches Methylation profiles of ccfDNA showed potential as a biomarker to stratify the severity of acute coronary syndromes, a novel non-invasive detection methodology that could be extrapolated to risk stratification in other cardiovascular disease such as heart failure or coronary artery disease.

Heart-specific DNA methylation analysis in plasma for the investigation of myocardial damage

Cardiac-specific methylation patterns of circulating DNA for identification of cardiomyocyte death

Methylome of circulating cell free DNA as a novel biomarker tool: from acute coronary syndrome to broader risk stratification of cardiovascular disease

Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA

Comprehensive DNA Methylation Analysis of Tissue of Origin of Plasma Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing (Mcta-Seq)

A sensitive method to quantify human cell-free circulating DNA in blood: relevance to myocardial infarction screening.

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA As Diagnostic and Predictive Biomarkers for Coronary Artery Disease

Integrative Analysis of DNA Methylation and Gene Expression Reveals Key Molecular Signatures in Acute Myocardial Infarction

Abstract 4135025: Inflammation-related 5-Hydroxymethylation Signatures As Markers for Clinical Presentations of Coronary Artery Disease

Distinct methylome profile of cfDNA in AMI patients reveals significant alteration in cAMP signaling pathway genes regulating cardiac muscle contraction

Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction.

Circulating microRNAs as novel biomarkers for dilated cardiomyopathy.

5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA As Candidate Diagnostic and Predictive Biomarkers for Coronary Artery Disease

Platelet Mitochondrial DNA Methylation: A Novel Biomarker for Myocardial Infarction - A Preliminary Study

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury

Global Surveillance of Circulating Microrna for Diagnostic and Prognostic Assessment of Acute Myocardial Infarction Based on the Plasma Small RNA Sequencing.

Identification of DNA Methylation-Regulated Genes As Potential Biomarkers for Coronary Heart Disease Via Machine Learning in the Framingham Heart Study

Genome-wide Methylation Analysis Reveals Differentially Methylated CpG Sites and Altered Expression of Heart Development-Associated Genes in Fetuses with Cardiac Defects

Epigenome-wide association study for dilated cardiomyopathy in left ventricular heart tissue identifies putative gene sets associated with cardiac development and early indicators of cardiac risk

Integrated DNA methylation and gene expression analysis in the pathogenesis of coronary artery disease

Genome-wide DNA methylation profiling in blood reveals epigenetic signature of incident acute coronary syndrome